Hyperlipidemia in dialysis patients: what treatment?
The incidence of hyperlipidemia in the dialysis population in our hospital reflects the incidence reported by other authors but we ascertained a high incidence of hypercholesterolemic patients. The importance of cardiovascular illnesses as the cause of death in patients on dialysis means taking into consideration risk factors. In our study, omega-3 fatty acids proved to be effective in about half the patients treated and did not have side effects. In a comparison of patients who underwent alternative techniques with high-flux membranes and those who underwent standard dialysis, the first group showed a virtually normal lipid profile. High-flux membranes could be a therapeutical possibility for hypertriglyceridemic patients under dialysis.
Iorio
L
L
G. DeBosis Hospital, Cassino, Italy.
Saltarelli
G
G
Nacca
R G
RG
Simonelli
R
R
Violi
F
F
D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D006949:Hyperlipidemias / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D015228:Hypertriglyceridemia / Q000188:drug therapy* / Q000209:etiology; D015994:Incidence; D006435:Renal Dialysis / Q000009:adverse effects*; D012307:Risk Factors
D015525:Fatty Acids, Omega-3